Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail

NCT01784536 is registered in ClinicalTrials.gov with Melinta Therapeutics, Inc. as lead sponsor.

NCT NCT01784536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01784536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail
Lead sponsor
Melinta Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2013
Completion date
March 31, 2013
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy